References
- 1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900.10.1016/S0735-1097(02)01886-7
- 2. Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131:e1502-8. doi: 10.1542/peds.2012-3435.10.1542/peds.2012-3435
- 3. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-13. doi: 10.1016/j.jpeds.2008.05.05910.1016/j.jpeds.2008.05.059
- 4. Yun SW. Congenital heart disease in the newborn requiring early intervention. Korean J Pediatr. 2011;54:183–91. doi: 10.3345/kjp.2011.54.5.18310.3345/kjp.2011.54.5.183
- 5. Olney RS, Ailes EC, Sontag MK. Detection of critical congenital heart defects: Review of contributions from prenatal and newborn screening. Semin Perinatol. 2015;39:230-7. doi: 10.1053/j.semperi.2015.03.007.10.1053/j.semperi.2015.03.007
- 6. American Institute of Ultrasound in Medicine. AIUM practice guideline for the performance of an antepartum obstetric ultrasound examination. J Ultrasound Med. 2003;22:1116–25.10.7863/jum.2003.22.10.1116
- 7. AIUM practice guideline for the performance of obstetric ultrasound examinations. J Ultrasound Med. 2010;29:157–66.10.7863/jum.2010.29.1.157
- 8. Momma K, Uemura S, Nishihara S, Ota Y. Dilatation of the ductus arteriosus by prostaglandins and prostaglandin’s precursors. Pediatr Res. 1980;14:1074-7. DOI: 10.1203/00006450-198009000-0001110.1203/00006450-198009000-00011
- 9. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics. 1977;59:325-9.10.1542/peds.59.3.325
- 10. Benson LN, Olley PM, Patel RG, Coceani F, Rowe RD. Role of prostaglandin E1 infusion in the management of transposition of the great arteries. Am J Cardiol.1979;44:691–6.10.1016/0002-9149(79)90289-3
- 11. Hundalani SG, Kulkarni M, Fernandes CJ, Cabrera AG, Shivanna B, Pammi M. Prostaglandin E1 for maintaining ductal patency in neonates with ductus-dependent cardiac lesions (Protocol). Cochrane Database of Systematic Reviews. 2014;12:CD011417. DOI: 10.1002/14651858.CD011417.10.1002/14651858.CD011417
- 12. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 2002;68-69:557-73.10.1016/S0090-6980(02)00055-2
- 13. Reese J, Veldman A, Shah L, Vucovich M, Cotton RB. Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Semin Perinatol. 2010;34:222-30. doi: 10.1053/j.semperi.2010.02.007.10.1053/j.semperi.2010.02.007
- 14. Buck ML. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport. DICP. 1991;25:408-9.10.1177/106002809102500413
- 15. Moldovan E, Cucerea M. Drug Closure of a Patent Ductus Arteriosus in An Extremely Low Birth Weight Premature Newborn. A Case Report. J Crit Care Med. 2015;1:28-32. DOI: 10.1515/jccm-2015-000610.1515/jccm-2015-0006
- 16. Dolbec K. Congenital heart disease. Emerg Med Clin North Am. 2011;29:811-27. doi: 10.1016/j.emc.2011.08.005.10.1016/j.emc.2011.08.005
- 17. Yaffe SJ, Aranda JV. Neonatal and Pediatric Pharmacology 4e: Therapeutic Principles In Practice. Lippincott Williams & Wilkins, Philadelphia, PA. 2011.
- 18. Toganel R. Critical Congenital Heart Diseases as Lifethreatening Conditions in the Emergency Room. Journal of Cardiovascular Emergencies. 2016;2:7-10. DOI: 10.1515/jce-2016-0002.10.1515/jce-2016-0002
- 19. Chamberlin M, Lozynski J. To go against nature: manipulating the neonatal ductusarteriosus with prostaglandin. Newborn and Infant Nursing Reviews. 2006;6:158-62. DOI: 10.1053/j.nainr.2006.05.001.10.1053/j.nainr.2006.05.001
- 20. Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet.1975;1:140e2.10.1016/S0140-6736(75)91432-4
- 21. Nelson textbook of paediatrics. Arch Dis Child 1983;58:942.
- 22. Olley PM, Coceani F, Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation.1976;53:728 e31.http://dx.doi.org/10.1161/01.CIR.53.4.728
- 23. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics.1977;59:325e9.10.1542/peds.59.3.325
- 24. Huang FK, Lin CC, Huang TC, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol. 2013;54:102-6. doi: 10.1016/j.pedneo.2012.10.007.10.1016/j.pedneo.2012.10.00723590954
- 25. Talosi G, Katona M, Túri S. Side-effects of long-term prostaglandin E(1) treatment in neonates. Pediatr Int. 2007;49:335-40. DOI: 10.1111/j.1442-200X.2007.02380.x10.1111/j.1442-200X.2007.02380.x17532831
- 26. Middleton P, Kelly AM, Brown J, Robertson M. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J. 2006;23:622-4. DOI: 10.1136/emj.2006.03591510.1136/emj.2006.035915256416516858095